Celldex Therapeutics, Inc. (NASDAQ:CLDX) CFO Samuel Bates Martin Sells 17,172 Shares

Celldex Therapeutics, Inc. (NASDAQ:CLDX) CFO Samuel Bates Martin sold 17,172 shares of Celldex Therapeutics stock in a transaction on Friday, June 14th. The shares were sold at an average price of $35.42, for a total value of $608,232.24. Following the transaction, the chief financial officer now owns 28,125 shares in the company, valued at $996,187.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Samuel Bates Martin also recently made the following trade(s):

• On Thursday, May 30th, Samuel Bates Martin sold 35,000 shares of Celldex Therapeutics stock. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00.

Celldex Therapeutics Price Performance

CLDX opened at $34.66 on Wednesday. Celldex Therapeutics, Inc. has a 1 year low of $22.11 and a 1 year high of $53.18. The stock has a fifty day moving average price of $37.54 and a 200 day moving average price of $39.06.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. Research analysts expect that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Strs Ohio lifted its position in shares of Celldex Therapeutics by 92.9% in the fourth quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 1,300 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 1st quarter worth about $147,000. CANADA LIFE ASSURANCE Co lifted its position in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Celldex Therapeutics by 34.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Celldex Therapeutics during the 4th quarter worth about $251,000.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on CLDX shares. Wolfe Research started coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 target price on the stock. Stifel Nicolaus started coverage on Celldex Therapeutics in a report on Tuesday. They issued a “buy” rating and a $58.00 target price on the stock. Guggenheim lifted their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Monday, June 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Tuesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $62.17.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.